{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:40:05Z","timestamp":1745311205776,"version":"3.40.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012615","name":"University of Texas Health Science Center at Houston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tranon.2025.102379","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:51:03Z","timestamp":1743900663000},"page":"102379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-5505","authenticated-orcid":false,"given":"Michael G.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-1047","authenticated-orcid":false,"given":"Reed I.","family":"Ayabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadl A.","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman M.G.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-6946","authenticated-orcid":false,"given":"Norman J.","family":"Galbraith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u2024Bryan","family":"Iorgulescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Scally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"Newhook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-288X","authenticated-orcid":false,"given":"Nancy Y.","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8238-8552","authenticated-orcid":false,"given":"Jason","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-5361","authenticated-orcid":false,"given":"George J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-3457","authenticated-orcid":false,"given":"Abhineet","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2025.102379_bib0001","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases - a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2025.102379_bib0002","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0003","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0004","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2025.102379_bib0005","article-title":"Prognostic value of KRAS gene mutation on survival of patients with peritoneal metastases of colorectal adenocarcinoma","volume":"2021","author":"Diez-Alonso","year":"2021","journal-title":"Int. J. Surg. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","article-title":"Prognostic Impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC","volume":"27","author":"Graf","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0007","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1158\/1078-0432.CCR-20-3320","article-title":"Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of \"Stemness\" programs and local inflammation","volume":"27","author":"Barriuso","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2025.102379_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-022-01742-5","article-title":"Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity","author":"Laoukili","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2025.102379_bib0009","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1245\/s10434-021-10291-9","article-title":"Surgical outcomes in cancer patients undergoing elective surgery after recovering from Mild-to-Moderate SARS-CoV-2 infection","volume":"28","author":"Kothari","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jmoldx.2013.05.003","article-title":"Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes","volume":"15","author":"Singh","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.tranon.2025.102379_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102976","article-title":"Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases","volume":"9","author":"Tonello","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.tranon.2025.102379_bib0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cancergen.2019.06.004","article-title":"Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA","volume":"237","author":"Shi","year":"2019","journal-title":"Cancer Genet."},{"key":"10.1016\/j.tranon.2025.102379_bib0013","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2025.102379_bib0014","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1158\/1078-0432.CCR-19-0863","article-title":"Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases","volume":"25","author":"Kawaguchi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2025.102379_bib0015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"1990","journal-title":"Stat. Med."},{"key":"10.1016\/j.tranon.2025.102379_bib0016","first-page":"2017","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0017","unstructured":"MD Anderson Cancer Center Personalized Cancer Therapy: Knowledge Base for Precision Oncology, <https:\/\/pct.mdanderson.org\/#\/home>(2024)."},{"key":"10.1016\/j.tranon.2025.102379_bib0018","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0019","article-title":"What is the risk for peritoneal metastases and survival afterwards in T4 colon cancers?","author":"Uppal","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00261-008-9372-z","article-title":"Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructions","volume":"34","author":"Franiel","year":"2009","journal-title":"Abdom. Imaging"},{"key":"10.1016\/j.tranon.2025.102379_bib0021","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0022","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0023","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/onco.13607","article-title":"Wild-type APC is associated with poor survival in metastatic microsatellite stable colorectal cancer","volume":"26","author":"Wang","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2025.102379_bib0024","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","article-title":"Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients","volume":"126","author":"Larsen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2025.102379_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7314\/APJCP.2016.17.2.539","article-title":"Value of KRAS, BRAF, and PIK3CA mutations and survival benefit from systemic chemotherapy in colorectal peritoneal carcinomatosis","volume":"17","author":"Sasaki","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.tranon.2025.102379_bib0026","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/bjs\/znac147","article-title":"KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations","volume":"109","author":"Olthof","year":"2022","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.tranon.2025.102379_bib0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejso.2018.02.247","article-title":"SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases","volume":"44","author":"Mizuno","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0028","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/SLA.0000000000002450","article-title":"Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases","volume":"269","author":"Chun","year":"2019","journal-title":"Ann. Surg."},{"key":"10.1016\/j.tranon.2025.102379_bib0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cancergencyto.2010.04.023","article-title":"Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer","volume":"202","author":"Idziaszczyk","year":"2010","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.tranon.2025.102379_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2025.102379_bib0032","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) Inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2025.102379_bib0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(17)30336-4","article-title":"Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer","volume":"18","author":"Tseng","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.632962","article-title":"KRAS mutational regression is associated with oligo-metastatic status and good prognosis in metastatic colorectal cancer","volume":"11","author":"Ottaiano","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0035","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1158\/1078-0432.CCR-20-0073","article-title":"Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy","volume":"26","author":"Narasimhan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2025.102379_bib0036","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejso.2019.09.008","article-title":"Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: a mouse model study","volume":"46","author":"Taibi","year":"2020","journal-title":"Eur. J. Surg. Oncol.: J. Eur. Society Surg. Oncol. British Associat. Surgical Oncol."},{"key":"10.1016\/j.tranon.2025.102379_bib0037","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/s41374-020-0448-x","article-title":"A mouse model for peritoneal metastases of colorectal origin recapitulates patient heterogeneity","volume":"100","author":"Bastiaenen","year":"2020","journal-title":"Lab. Invest."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332500110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332500110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:58:20Z","timestamp":1745308700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332500110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":37,"alternative-id":["S193652332500110X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102379","relation":{},"ISSN":["1936-5233"],"issn-type":[{"type":"print","value":"1936-5233"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102379"}}